back to the overview


Ad-hoc-Release; Berlin, January 2, 2007


MOLOGEN AG acquires innovative technology


The Berlin-based biotechnology company MOLOGEN announced today that it has concluded an agreement with Netherlands based Synvolux Therapeutics B.V. ("Synvolux") regarding the use of the SAINT technology developed by Synvolux.

The SAINT technology offers a unique, secure and efficient method for the application of DNA molecules such as MIDGE and dSLIM. With the help of SAINT, MIDGE based DNA vaccines and dSLIM immunomodulators can more easily reach certain skin layers and be more easily absorbed in the cells after a typical syringe injection. Where biomedically practical, this technology also allows MIDGE and dSLIM to be absorbed through the skin without injection.

"Through the use of this highly innovative technology, we are in a position to optimize our own DNA vaccines and DNA therapeutics", according to Prof Dr Burghardt Wittig, Chief Executive Officer of MOLOGEN AG. "For example, this allows us to reduce the dosage of our DNA medicines and improve their effectiveness at the same time.

"The agreement with Synvolux represents a significant investment in financial year 2006. The profit and loss statements for 2006 will only be marginally influenced through these transactions, however.



MOLOGEN AG is a listed biopharmaceutical company with headquarters in Berlin (Frankfurt Stock Exchange, Regulated Market, ISIN DE0006637200). On the basis of patented technologies (MIDGE and dSLIM), MOLOGEN develops DNA-based vaccines and therapeutic agents for the prevention and treatment of a wide range of serious illnesses.


Disclaimer concerning prognoses

Certain statements in this communication contain formulations or terms referring to the future or future developments, as well as negations of such formulations or terms, or similar terminology. These are described as forward-looking statements. In addition, all information in this communication regarding planned or future results of business segments, financial classification numbers, developments of the financial situation, or other financial or statistical data contains such forward-looking statements. The company cautions prospective investors not to rely on such forward-looking statements as certain prognoses of actual future events and developments. The company is neither responsible nor liable for these forward-looking statements. It is not responsible for updating such information, which only represents the state of affairs on the day of publication.


 back to the overview


Investor & Public Relations

  Joerg Petrass

Research & Development

  Dr. Matthias Schroff

Business Development

  Arlett Killat


To subscribe to our Newsletter please

 click here


To view our Reports

  click here